In this study, the investigators evaluated 79 treatment naïve primary breast cancer tumor samples from a clinical trial where patients were given the current standard of care therapy with the addition of a novel immunotherapy. Biopsies from 3 different timepoints were collected as part of the study.   FFPE samples from these patients were evaluated on the BC360 panel to understand what combination of clinical and molecular features could best be used to identify responders and non-responders to the immunotherapy at time of diagnosis.  The Tumor Inflammation Signature (TIS) and INF Gamma signatures were strong predictors of response to the combination therapy in this study. While hormone receptor (HR) status showed expected differences in signatures, these differences were not enough to define responders and non-responders.  Two additional signatures, HRD and p53, and multiple genes were also significantly associated with response in this study.